Cite
MLA Citation
Maribel G. Vallespi et al.. “A first‐in‐class, first‐in‐human, phase I trial of CIGB‐552, a synthetic peptide targeting COMMD1 to inhibit the oncogenic activity of NF‐κB in patients with advanced solid tumors.” International journal of cancer, vol. 149, no. 6, 2021, pp. 1313–1321. http://access.bl.uk/ark:/81055/vdc_100135172052.0x00005e